Selective interactions of polyanions with basic surfaces on human immunodeficiency virus type 1 gp120

Journal of Virology

Volumn 74, Issue 4, 2000, Pages 1948-1960

  Moulard, Maxime ^a,g   Lortat Jacob, Hugues ^b   Mondor, Isabelle ^a   Roca, Guillaume ^a   Wyatt, Richard ^c   Sodroski, Joseph ^c   Zhao, Lu ^d   Olson, William ^d   Kwong, Peter D ^e   Sattentau, Quentin J ^a,f  

^a CENTRE D IMMUNOLOGIE DE MARSEILLE LUMINY   (France)

^b INSTITUT DE BIOLOGIE STRUCTURALE   (France)

^c HARVARD MEDICAL SCHOOL   (United States)

^d Clinical Research   (United States)

^e New York Presbyterian Columbia University Medical Center   (United States)

^f IMPERIAL COLLEGE LONDON   (United Kingdom)

^g SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; GLYCOPROTEIN GP 120; POLYANION;

ARTICLE; BINDING SITE; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR MODEL; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; VIRUS INFECTIVITY;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD4; BINDING SITES; ELECTROSTATICS; EPITOPES, B-LYMPHOCYTE; HEPARIN; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; MUTAGENESIS; PEPTIDE FRAGMENTS; POLYMERS; RECEPTORS, CXCR4; SULFUR RADIOISOTOPES; SURFACE PLASMON RESONANCE; TUMOR CELLS, CULTURED;

EID: 0033920212     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.74.4.1948-1960.2000     Document Type: Article

References (92)

1. Abrams, D. I., S. Kuno, R Wong, K. Jeffords, M. Nash, J. B. Molaghan, R. Gorter, and R. Ueno. 1989. Oral dextran sulfate (UA001) in the treatment of the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. Ann. Intern. Med. 110:183-188.
2. Bagasra, O., and H. W. Lischner. 1988. Activity of dextran sulfate and other polysaccharides against human immunodeficiency virus. J. Infect. Dis. 158: 1084-1087.
3. Batinic, D., and F. A. Robey. 1992. The V3 region of the envelope glycoprotein of human immunodeficiency virus type 1 binds sulfated polysaccharides and CD4-derived synthetic peptides. J. Biol. Chem. 267:6664-6671.
4. Berger, E. A., R. W. Doms, E.-M. Fenyo, B. T. M. Korber, D. R. Littman, J. P. Moore, Q. J. Sattentau, H. Schuitemaker, J. Sodroski, and R. A. Weiss. 1997. HIV-1 phenotypes classified by co-receptor usage. Nature 391:240.
5. Brelot, A., N. Heveker, O. Pleskoff, N. Sol, and M. Alizon. 1997. Role of the first and third extracellular domains of CXCR-4 in human immunodeficiency virus coreceptor activity. J. Virol. 71:4744-4751.
6. Bugelski, P. J., H. Eltens, T. K. Hart, and R. L. Kirsh. 1991. Soluble CD4 and dextran sulfate mediate release of gp120 from HIV-1: implications for clinical trials. J. Acquir. Immune Defic. Syndr. 4:923-924.
7. Burton, D. R., J. Pyati, R. Koduri, S. J. Sharp, G. B. Thornton, P. W. Parren, L. S. Sawyer, R. M. Hendry, N. Dunlop, P. L. Nara, and D. Burton. 1994. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 264:1024-1027.
8. Callahan, L. N., M. Phelan, M. Mallinson, and M. A. Norcross. 1991. Dextran sulfate blocks antibody binding to the principal neutralizing domain of human immunodeficiency virus type 1 without interfering with gp120-CD4 interactions. J. Virol. 65:1543-1550.
9. Catasti, P., J. D. Fontenot, E. M. Bradbury, and G. Gupta. 1995. Local and global structural properties of the HIV-MN V3 loop. J. Biol. Chem. 270: 2224-2232.
10. Chen, Y., T. Maguire, R. E. Hileman, J. R. Fromm, J. D. Esko, R. J. Linhardt, and R. M. Marks. 1997. Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate. Nat. Med. 3:866-871.
11. Cho, M. W., M. K. Lee, M. C. Carney, J. F. Berson, R. W. Doms, and M. A. Martin. 1998. Identification of determinants on a dualtropic human immunodeficiency virus type 1 envelope glycoprotein that confer usage of CXCR4. J. Virol. 72:2509-2515.
12. Choe, H., M. Farzan, Y. Sun, N. Sullivan, B. Rollins, P. D. Ponath, L. Wu, C. R. Mackay, G. LaRosa, W. Newman, N. Gerard, C. Gerard, and J. Sodroski. 1996. The β-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 85:1135-1148.
13. Chung, C.-S., J.-C. Hsiao, Y.-S. Chang, and W. Chang. 1998. A27L protein mediates vaccinia virus interaction with cell surface heparan sulfate. J. Virol. 72:1577-1585.
14. Cocchi, F., A. L. DeVico, A. Garzino-Demo, A. Cara, R. C. Gallo, and P. Lusso. 1996. The V3 domain of the HIV-1 gp120 envelope glycoprotein is critical for chemokine-mediated blockade of infection. Nat. Med. 2:1244-1247.
15. Conky, A. J., M. K. Gorny, J. A. Kessler II, L. J. Boots, M. Ossorio-Castro, S. Koenig, D. W. Lineberger, E. A. Emini, C. Williams, and S. Zolla-Pazner. 1994. Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52D. J. Virol. 68:6994-7000.
16. Deen, K. C., J. S. McDougal, R. Inacker, G. Folena-Wasserman, J. Arthos, J. Rosenberg, P. J. Maddon, R. Axel, and R. W. Sweet. 1988. A soluble form of CD4 (T4) protein inhibits AIDS virus infection. Nature 331:82-84.
17. Dimitrov, D. S., and C. C. Broder. 1997. HIV and membrane receptors. Landes Bioscience, Austin, Tex.
18. Ditzel, H. J., P. W. H. I. Parren, J. Binley, J. Sodroski, J. P. Moore, C. F. Barbas, and D. R. Burton. 1997. Mapping the protein surface of HIV-1 gp120 using human monoclonal antibodies from phage display libraries. J. Mol. Biol. 267:684-689.
19. Doms, R. W., A. L. Edinger, and J. P. Moore. 1998. Coreceptor use by primate lentiviruses. Los Alamos National Laboratory, Los Alamos, N.Mex.
20. Doms, R. W., and S. C. Peiper. 1997. Unwelcomed guests with master keys: how HIV uses chemokine receptors for cellular entry. Virology 235:179-190.
21. Dragic, T., A. Trkola, S. W. Lin, K. A. Nagashima, F. Kajumo, L. Zhao, W. C. Olson, L. Wu, C. R. Mackay, G. P. Allaway, T. P. Sakmar, J. P. Moore, and P. J. Maddon. 1998. Amino-terminal substitutions in the CCR5 coreceptor impair gp120 binding and human immunodeficiency virus type 1 entry. J. Virol. 72:279-285.
22. Este, J. A., D. Schols, K. De Vreese, K. Van Laethem, A. M. Vandamme, J. Desmyter, and E. De Clercq. 1997. Development of resistance of human immunodeficiency virus type 1 to dextran sulfate associated with the emergence of specific mutations in the envelope gp120 glycoprotein. Mol. Pharmacol. 52:98-104.
23. Farzan, M., H. Choe, L. Vaca, K. Martin, Y. Sun, E. Desjardins, N. Ruffing, L. Wu, R. Wyatt, N. Gerard, C. Gerard, and J. Sodroski. 1998. A tyrosinerich region in the N terminus of CCR5 is important for human immunodeficiency virus type 1 entry and mediates an association between gp120 and CCR5. J. Virol. 72:1160-1164.
24. Farzan, M., T. Mirzabekov, P. Kolchinsky, R. Wyatt, M. Cayabyab, N. P. Gerard, C. Gerard, J. Sodroski, and H. Choe. 1999 Tyrosine sulfation of the amino terminus of CCR5 facilitates HIV-1 entry. Cell 96:667-676.
25. Fisher, A. G., B. Ensoli, D. Looney, A. Rose, R. C. Gallo, M. S. Saag, G. M. Shaw, et al. 1988. Biologically diverse molecular variants within a single HIV-1 isolate. Nature 334:444-447.
26. Flexner, C., P. A. Barditch-Crovo, D. M. Kornhauser, H. Farzadegan, L. J. Nerhood, R. E. Chaisson, K. M. Bell, K. J. Lorentsen, C. W. Hendrix, B. G. Petty, and P. S. Lietman. 1991. Pharmacokinetics, toxicity, and activity of intravenous dextran sulfate in human immunodeficiency virus infection. Antimicrob. Agents Chemother. 35:2544-2550.
27. Flynn, S. J., and P. Ryan. 1995. A heterologous heparin-binding domain can promote functional attachment of a pseudorabies virus gC mutant to cell surfaces. J. Virol. 69:834-839.
28. Fouchier, R. A. M., M. Groenink, N. A. Kootstra, M. Tersmette, H. G. Huisman, F. Miedema, and H. Schuitemaker. 1992. Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule. J. Virol. 66:3183-3187.
29. Fry, E. E., S. M. Lea, T. Jackson, J. W. I. Newman, F. M. Ellard, W. E. Blakemore, R. Abu-Ghazaleh, A. Samuel, A. M. Q. King, and D. I. Stuart. 1999. The structure and function of a foot and mouth disease virus-oligosaccharide receptor complex. EMBO J. 18:543-554.
30. Gordon, M., S. Decks, C. De Marzo, J. Goodgame, M. Guralnik, W. Lang, T. Mimura, D. Pearce, and Y. Kaneko. 1997. Curdlan sulfate (CRDS) in a 21-day intravenous tolerance study in human immunodeficiency virus (HIV) and cytomegalovirus (CMV) infected patients: indication of anti-CMV activity with low toxicity. J. Med. 28:108-128.
31. Gorny, M. K., A. J. Conley, S. Karwowska, A. Buchbinder, J.-Y. Xu, E. A. Emini, S. Koenig, and S. Zolla-Pazner. 1992. Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody. J. Virol. 66:7538-7542.
32. Harrop, H. A., D. R. Coombe, and C. C. Rider. 1994. Heparin specifically inhibits binding of V3 loop antibodies to HIV-1 gp120, an effect potentiated by CD4 binding. AIDS 8:183-192.
33. Harrop, H. A., and C. C. Rider. 1998. Heparin and its derivatives bind to HIV-1 recombinant envelope glycoproteins, rather than to recombinant HIV-1 receptor, CD4. Glycobiology 8:131-137.
34. Haywood, A. M. 1994. Virus receptors: binding, adhesion strengthening, and changes in viral structure. J. Virol. 68:1-5.
35. + cells from virus binding. J. Exp. Med. 172: 1233-1242.
36. Hiebert, L. M., S. M. Wice, L. B. Jaques, K. E. Williams, and J. M. Conly. 1999. Orally administered dextran sulfate is absorbed in HIV-positive individuals. J. Lab. Clin. Med. 133:161-170.
37. Hoffman, T. L., and R. W. Doms. 1999. HIV-1 envelope determinants for cell tropism and chemokine receptor use. Mol. Membr. Biol. 16:57-65.
38. Hoffman, T. L., C. C. LaBranche, W. Zhang, G. Canziani, J. Robinson, I. Chaiken, J. A. Hoxie, and R. W. Doms. 1999. Stable exposure of the coreceptor-binding site in a CD4-independent HIV-1 envelope protein. Proc. Natl. Acad. Sci. USA 96:6359-6364.
39. Honig, B., and A. Nicholls. 1995. Classical electrostatics in biology and chemistry. Science 268:1144-1149.
40. Ibrahim, J., P. Griffin, D. R. Coombe, C. C. Rider, and W. James. 1999. Cell-surface heparan sulfate facilitates human immunodeficiency virus type 1 entry into some cell lines but not primary lymphocytes. Virus Res. 60:159-169.
41. Ito, M., M. Baba, A. Sato, R. Pauwels, E. de Clercq, and S. Shigeta. 1987. Inhibitory effect of dextran sulfate and heparin on the replication of human immunodeficiency virus (HIV) in vitro. Antivir. Res. 7:361-367.
42. Jiang, S. 1997. HIV-1-coreceptor binding. Nat. Med. 3:367-368.
43. Karlson, R., H. Roos, L. Fagerstam, and B. Persson. 1994. Kinetic and concentration analysis using BIA technology. Methods 6:99-110.
44. Kwong, P. D., R. Wyatt, J. Robinson, R. W. Sweet, J. Sodroski, and W. A. Hendrickson. 1998. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393:648-659.
45. Kwong, P. D., R. Wyatt, Q. J. Sattentau, J. Sodroski, and W. A. Hendrickson. 2000. Oligomeric modeling and electrostatic analysis of the gp120 envelope glycoprotein of human immunodeficiency virus. J. Virol. 74:1961-1972.
46. Lee, M. K., J. Heaton, and M. W. Cho. 1999. Identification of determinants of interaction between CXCR4 and gp120 of a dual-tropic HIV-1DH12 isolate. Virology 257:290-296.
47. Lorentsen, K. J., C. W. Hendrix, J. M. Collins, D. M. Kornhauser, B. G. Petty, R. W. Klecker, C. Flexner, R. H. Eckel, and P. S. Lietman. 1989. Dextran sulfate is poorly absorbed after oral administration. Ann. Intern. Med. 111:561-566.
48. + cells. Science 240:646-649.
49. 2-termini and V1/V2 and V3 loops, and sensitivity to neutralizing antibodies. Virology 248:394-405.
50. Mondor, I., S. Ugolini, and Q. J. Sattentau. 1998. Human immunodeficiency virus type 1 attachment to HeLa CD4 cells is CD4-independent and gp120 dependent and requires cell surface heparans. J. Virol. 72:3623-3634.
51. Moore, J. P., J. A. McKeating, R. A. Weiss, and Q. J. Sattentau. 1990. Dissociation of gp120 from HIV-1 virions induced by soluble CD4. Science 250:1139-1142.
52. Moore, J. P., Q. J. Sattentau, R. Wyatt, and J. Sodroski. 1994. Probing the structure of the human immunodeficiency virus surface glycoprotein gp120 with a panel of monoclonal antibodies. J. Virol. 68:469-484.
53. Moore, J. P., A. Trkola, B. Korber, L. J. Boots, J. A. Kessler II, F. E. McCutchan, J. Mascola, D. D. Ho, J. Robinson, and A. J. Conley. 1995. A human monoclonal antibody to a complex epitope in the V3 region of gp120 of human immunodeficiency virus type 1 has broad reactivity within and outside clade B. J. Virol. 69:122-130.
54. Morton, T. A., D. G. Myszka, and I. M. Chaiken. 1995. Interpreting complex binding kinetics from optical biosensors: a comparison of analysis by linearization, the integration rate equation, and numerical integration. Anal. Biochem. 227:176-185.
55. Nicholls, A., and B. Honig. 1991. A rapid finite difference algorithm, utilizing successive over-relaxation to solve the Poisson-Boltzmann equation. J. Comput. Chem. 12:435-445.
56. Nicholls, A., K. A. Sharp, and B. Honig. 1991. Protein folding and association: insight from the interfacial and thermodynamic properties of hydrocarbons. Proteins Struct. Funct. Genet. 11:281-296.
57. Ohshiro, Y., T. Murakami, K. Matsuda, K. Nishioka, K. Yoshida, and N. Yamamoto. 1996. Role of cell surface glycosaminoglycans of human T cells in human immunodeficiency virus type 1 (HIV-1) infection. Microbiol. Immunol. 40:827-835.
58. Oravecz, T., M. Pall, and M. A. Norcross. 1996. β-Chemokine inhibition of monocytotropic HIV-1 infection. J. Immunol. 157:1329-1332.
59. Patel, M., M. Yanagishita, G. Roderiquez, D. C. Bou-Habib, T. Oravecz, V. C. Hascall, and M. A. Norcross. 1993. Cell-surface heparan sulfate proteoglycan mediates HIV-1 infection of T-cell lines. AIDS Res. Hum. Retrovir. 9:167-174.
60. + cells expressing the rat homolog of CXCR-4 (fusin). J. Virol. 71:3259-3262.
61. Prince, A. M., B. Horowitz, L. Baker, R. W. Schulman, H. Ralph, J. Valinski, A. Cundell, B. Brotman, W. Boehle, F. Rey, M. Piet, H. Reesink, N. Lelie, M. Tersmette, L. Barbosa, G. Nemo, C. L. Nastala, J. S. Allan, D. R. Lee, and J. W. Eichberg. 1988. Failure of a human immunodeficiency virus (HIV) immune globulin to protect chimpanzees against experimental challenge with HIV. Proc. Natl. Acad. Sci. USA 85:6944-6948.
62. Rabut, G. E. E., J. A. Konner, F. Kajumo, J. P. Moore, and T. Dragic. 1998. Alanine substitutions of polar and nonpolar residues in the amino-terminal domain of CCR5 differently impair entry of macrophage-and dualtropic isolates of human immunodeficiency virus type 1. J. Virol. 72:3464-3468.
63. Rider, C. C., D. R. Coombe, H. A. Harrop, E. F. Hounsell, C. Bauer, J. Feeney, B. Mulloy, N. Mahmood, A. Hay, and C. Parish. 1994. Anti-HIV-1 activity of chemically modified heparins: correlation between binding to the V3 loop of gp120 and inhibition of cellular HIV-1 infection in vitro. Biochemistry 33:6974-6980.
64. Rizzuto, C. D., R. Wyatt, N. Hernandez-Ramos, Y. Sun, P. D. Kwong, W. A. Hendrickson, and J. Sodroski. 1998. A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. Science 280:1763-1767.
65. Roderiquez, G., T. Oravecz, M. Yanagishita, D. C. Bou-Habib, H. Mostowski, and M. A. Noreross. 1995. Mediation of human immunodeficiency virus type 1 binding by interaction of cell surface heparan sulfate proteoglycans with the V3 region of envelope gp120-gp41. J. Virol. 69:2233-2239.
66. Roskams, T., H. Moshage, R. De Vos, D. Guido, P. Yap, and V. Desmet. 1995. Heparan sulfate proteoglycan expression in normal human liver. Hepatology 21:950-958.
67. Ross, T. M., and B. R. Cullen. 1998. The ability of HIV type 1 to use CCR-3 as a coreceptor is controlled by envelope V1/V2 sequences acting in conjunction with a CCR-5 tropic V3 loop. Proc. Natl. Acad. Sci. USA 95:7682-7686.
68. Sattentau, Q. J. 1998. HIV gp120: double lock strategy foils host defences. Structure 6:945-949.
69. Sattentau, Q. J., and J. P. Moore. 1995. Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer. J. Exp. Med. 182:185-196.
70. Scarlatti, G., E. Trersoldi, A. Bjorndal, R. Fredriksson, C. Colognesi, H. K. Deng, M. S. Malnati, A. Plebani, A. G. Siccardi, D. R. Littman, E. M. Fenyo, and P. Lusso. 1997. In vivo evolution of HIV-1 coreceptor usage and sensitivity to chemokine-mediated suppression. Nat. Med. 3:1259-1265.
71. Secchiero, P., D. Sun, A. L. De Vico, R. W. Crowley, M. S. Reitz, Jr., G. Zauli, P. Lusso, and R. C. Gallo. 1997. Role of the extracellular domain of human herpesvirus 7 glycoprotein B in virus binding to cell surface heparan sulfate proteoglycans. J. Virol. 71:4571-4580.
72. Smyth, R. J., Y. Yi, A. Singh, and R. G. Collman. 1998. Determinants of entry cofactor utilization and tropism in a dualtropic human immunodeficiency virus type 1 primary isolate. J. Virol. 72:4478-4484.
73. Speck, R. F., K. Wehrly, E. J. Platt, R. E. Atchison, I. F. Charo, D. Kabat, B. Chesebro, and M. A. Goldsmith. 1997. Selective employment of chemokine receptors as human immunodeficiency virus type 1 coreceptors determined by individual amino acids within the envelope V3 loop. J. Virol. 71:7136-7139.
74. Stafford, M. K., D. Cain, I. Rosenstein, E. A. Fontaine, M. McClure, A. M. Flanagan, J. R. Smith, D. Taylor-Robinson, J. Weber, and V. S. Kitchen. 1997. A placebo-controlled double blind prospective study in healthy female volunteers of dextrin sulfate gel: a novel potential intravaginal virucide. J. Acquir. Immune Defic. Syndr. 14:213-218.
75. Sullivan, N., Y. Sun, Q. Sattentau, M. Thali, D. Wu, G. Denisova, J. Gershoni, J. Robinson, J. Moore, and J. Sodroski. 1998. CD4-induced conformational changes in the human immunodeficiency virus type 1 gp120 glycoprotein: consequences for virus entry and neutralization. J. Virol. 72: 4694-4703.
76. Summerford, C., and R. J. Samulski. 1998. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J. Virol. 72:1438-1445.
77. Thali, M., J. P. Moore, C. Furman, M. Charles, D. D. Ho, J. Robinson, and J. Sodroski. 1993. Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding. J. Virol. 67:3978-3988.
78. Trkola, A., T. Dragic, J. Arthos, J. M. Binley, W. C. Olson, G. P. Allaway, C. Cheng-Mayer, J. Robinson, P. J. Maddon, and J. P. Moore. 1996. CD4-dependent, antibody sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature 384:184-187.
79. Trkola, A., A. B. Pomales, H. Yuan, B. Korber, P. J. Maddon, G. P. Allaway, H. Katinger, C. F. Barbas III, D. R. Burton, D. D. Ho, and J. P. Moore. 1995. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J. Virol. 69:6609-6617.
80. Trkola, A., M. Purtscher, T. Muster, C. Ballaun, A. Buchacher, N. Sullivan, K. Srinivasan, J. Sodroski, J. P. Moore, and H. Katinger, 1996. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J. Virol. 70: 1100-1108.
81. Tufaro, F. 1997. Virus entry: two receptors are better than one. Trends Microniol. 5:257-260.
82. Ueno, R., and S. Kuno. 1997. Dextran sulfate, a potent anti-HIV agent in vitro having synergism with zidovudine. Lancet i:1379.
83. Ugolini, S., I. Mondor, and Q. J. Sattentau. 1998. HIV-1 attachment: a second look. Trends Microbiol. 7:144-149.
84. + cells induces an interaction between CD4, gp120 and the chemokine receptor CXCR4. J. Immunol. 159:3000-3008.
85. Verrier, F., A. M. Borman, D. Brand, and M. Girard. 1999. Role of the HIV type 1 glycoprotein 120 V3 loop in determining coreceptor usage. AIDS Res. Hum. Retrovir. 15:731-743.
86. Warrier, S. V., A. Pinter, W. J. Honnen, M. Girard, E. Muchmore, and S. A. Tilley. 1994. A novel, glycan-dependent epitope in the V2 domain of human immunodeficiency virus type 1 gp120 is recognized by a highly potent, neutralizing chimpanzee monoclonal antibody. J. Virol. 68:4636-4642.
87. Wu, L., N. P. Gerard, R. Wyatt, H. Choe, C. Parolin, N. Ruffing, A. Borsetti, A. A. Cardoso, E. Desjardin, W. Newman, C. Gerard, and J. Sodroski. 1996. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature 384:179-183.
88. Wyatt, R., P. Kwong, E. Desjardins, R. W. Sweet, J. Robinson, W. A. Hendrickson, and J. G. Sodroski. 1998. The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 393:705-711.
89. Wyatt, R., J. Moore, M. Accola, E. Desjardin, J. Robinson, and J. Sodroski. 1995. Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding. J. Virol. 69:5723-5733.
90. Wyatt, R., and J. Sodroski. 1998. The HIV-1 envelope glycoproteins: fusogens, antigens and immunogens. Science 280:1884-1888.
91. Wyatt, R., N. Sullivan, M. Thali, H. Repke, D. Ho, J. Robinson, M. Posner, and J. Sodroski. 1993. Functional and immunologic characterization of human immunodeficiency virus type 1 envelope glycoproteins containing deletions of the major variable regions. J. Virol. 67:4557-4565.
92. Xiao, L., S. M. Owen, I. Goldman, A. A. Lal, J. J. deJong, J. Goudsmit, and R. B. Lal. 1998. CCR5 coreceptor usage of non-syncytium-inducing primary HIV-1 is independent of phylogenetically distinct global HIV-1 isolates: delineation of consensus motif in the V3 domain that predicts CCR-5 usage. Virology 240:83-92.